DDInter1380 DDInter1840
Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004.
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Palifermin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fludarabine
Fludarabine {u} (Compound) causes {v} (Side Effect) Myalgia
Myalgia {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Palifermin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bexarotene
Bexarotene {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Trabectedin
Palifermin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Altretamine
Altretamine {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Alkylating Activity {u} (Pharmacologic Class) includes {v} (Compound) Trabectedin
Palifermin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pazopanib
Pazopanib {u} (Compound) upregulates {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine and Fludarabine (Compound) causes Myalgia (Side Effect) and Myalgia (Side Effect) is caused by Trabectedin (Compound)
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Trabectedin (Compound)
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Altretamine and Altretamine (Compound) is included by Alkylating Activity (Pharmacologic Class) and Alkylating Activity (Pharmacologic Class) includes Trabectedin (Compound)
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib (Compound) upregulates SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)